Nutrien Ltd. (NYSE:NTR) Stock Has Consensus Price Target of $79.24 According to Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: 16 of 23 covering firms rate Nutrien a buy, six recommend holding, and one recommends selling. The average one-year price target is $79.24.
• Recent analyst targets varied: Morgan Stanley lowered its target to $81 while retaining an overweight rating; RBC maintained an $85 target and outperform rating. UBS raised its target to $62 but kept a sell rating.
• In its latest reported quarter, Nutrien’s EPS of $2.61 missed the $2.70 consensus, while revenue of $10.81 billion exceeded estimates and increased 3.6% year over year.

Shares of Nutrien Ltd. (NYSE:NTR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-three ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $79.24.

A number of brokerages have recently commented on NTR. Morgan Stanley dropped their target price on shares of Nutrien from $93.00 to $81.00 and set an "overweight" rating on the stock in a report on Tuesday, July 7th. Royal Bank Of Canada reissued an "outperform" rating and set a $85.00 price objective on shares of Nutrien in a research note on Friday, September 18th. National Bank Financial cut their price objective on shares of Nutrien from $76.00 to $74.00 and set an "outperform" rating on the stock in a report on Monday, August 10th. UBS Group raised their target price on shares of Nutrien from $59.00 to $62.00 and gave the company a "sell" rating in a research note on Tuesday, October 27th. Finally, Oppenheimer reduced their price objective on Nutrien from $80.00 to $78.00 and set an "outperform" rating for the company in a research report on Thursday, October 22nd.

Nutrien Price Performance

NTR stock opened at $69.18 on Wednesday. The company has a market cap of $32.88 billion, a P/E ratio of 14.00, a PEG ratio of 0.78 and a beta of 0.67. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.39 and a quick ratio of 0.86. The firm has a 50-day moving average of $72.94 and a 200 day moving average of $71.04. Nutrien has a 1 year low of $53.03 and a 1 year high of $85.36.

Nutrien (NYSE:NTR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.61 earnings per share for the quarter, missing the consensus estimate of $2.70 by ($0.09). The firm had revenue of $10.81 billion for the quarter, compared to the consensus estimate of $10.44 billion. Nutrien had a net margin of 8.44% and a return on equity of 8.88%. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.65 earnings per share. On average, sell-side analysts forecast that Nutrien will post 4.53 EPS for the current year.

Institutional Trading of Nutrien

Several institutional investors have recently bought and sold shares of NTR. Wellington Management Group LLP bought a new stake in shares of Nutrien during the 2nd quarter valued at $654,081,000. Deutsche Bank AG purchased a new stake in shares of Nutrien in the 2nd quarter worth $588,720,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Nutrien in the 2nd quarter worth $375,178,000. Canada Pension Plan Investment Board bought a new position in Nutrien in the 2nd quarter worth $359,318,000. Finally, BlackRock Inc. bought a new position in Nutrien in the 2nd quarter worth $220,942,000. 63.10% of the stock is owned by hedge funds and other institutional investors.

Nutrien Company Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.